Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2023-08-14 Interim / Quarterly Rep…
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2023
2023-08-14 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by ProMIS Neurosciences Inc. It primarily reports the company's continuance from incorporation under the Canada Business Corporations Act to the Business Corporations Act (Ontario). The document includes detailed legal and corporate governance information about the continuance, its effects on shareholder rights, and a comparison of the two corporate statutes. It is not a financial report, earnings release, or management discussion. It is a regulatory filing reporting a material corporate event and changes in corporate governance and shareholder rights. The document is lengthy (15,000 characters) and contains substantive information, not just an announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-07-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by ProMIS Neurosciences Inc. regarding a corporate continuance (changing jurisdiction of incorporation from federal CBCA to provincial OBCA). This is a standard regulatory filing detailing a material corporate event, which falls under the 'Regulatory Filings' category as it does not fit into more specific categories like M&A or financial reporting.
2023-07-14 English
424B3
Delisting Announcement Classification · 95% confidence The document is a Form 8-K Current Report filed by ProMIS Neurosciences Inc. It announces the voluntary delisting of the company's common shares from the Toronto Stock Exchange (TSX) and the consolidation of trading on the Nasdaq exchange. The document includes a press release about the delisting approval and the expected last trading day on the TSX. There are no financial statements or detailed financial data included; the filing is primarily an announcement of a corporate event related to the company's stock listing status. This fits the definition of a Delisting Announcement (DLST), which is an official notice that the company's stock will be removed from an exchange. The document length is sufficient and contains substantive information about the delisting event, not just a brief mention or a report publication announcement. Therefore, the appropriate classification is DLST with high confidence.
2023-07-10 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by ProMIS Neurosciences Inc. The key content is an announcement of the company's voluntary delisting of its common shares from the Toronto Stock Exchange (TSX), effective July 21, 2023, while continuing to trade on Nasdaq. The document includes a press release as an exhibit and does not contain financial statements or detailed financial data. The primary purpose is to notify the market of the delisting event. According to the filing definitions, an official notice that the company's stock will be removed from an exchange is classified as a Delisting Announcement (DLST). The document length is 3361 characters, which is short and focused on the delisting event, not a full financial report or other type of filing. Therefore, the correct classification is DLST with high confidence.
2023-07-10 English
424B3
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 30, 2023, reporting the results of shareholder votes at the company's 2023 annual meeting. It details the voting outcomes for director elections, appointment of auditors, and approval of corporate jurisdiction continuance. The content focuses on the official results of shareholder votes rather than the meeting materials or the annual report itself. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8155 characters) and detailed vote counts support that this is a full voting results announcement, not just a brief notice or proxy solicitation. Therefore, the correct classification is DVA with high confidence.
2023-06-30 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.